MU Logo Department of Internal Medicine at MUMu Health Care

Selected Publications

Dr. Perry
Manuscripts (selected since 1990)
  1. Dillman RO, Seagren SL, Propert K, Guerra J, Eaton WL, Perry MC, Carey R, Frei EF III, and Greene MR: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990.
  2. Cella DF, Orav EJ, Kornblith AB, Holland JC, Silberfarb PM, Lee KW, Perry MC, et al: Socioeconomic status and cancer survival. J Clin Onc 9:1500-1509, 1991.
  3. Oster MW, Schilsky RL, Faraggi D, Korzun AH, Perry MC, et al: Cytosine arabinoside and cisplatin for advanced breast cancer. Cancer 68:1696-1698, 1991.
  4. Doll D, Goutsou M, Graziano S, Ellerton J, Bitran J, Modeas C, Herndon J, Perry M, and Green M: Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. Cancer Chemother and Pharmacol 29:71-74, 1991.
  5. Komp, DM, Perry, MC: The histiocytic syndromes. Semin in Onc 18(1):1-2, 1991.
  6. Aisner J, Goutsou M, Maurer L, Cooper R, Chahinian P, Carey R, Skarin A, Slawson R, Perry M, Green M: Intensive combination chemotherapy, concurrent chest irradiation and warfarin for the treatment of limited disease small cell lung cancer: A CALGB Pilot Study. J Clin Onc 10:8:1230-1236, 1992.
  7. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al: A Meta-Analysis of thoracic radiotherapy for small-cell lung cancer. N Eng J Med 327:1618-1624, 1992.
  8. Vokes EE, Lyss AP, Green MR, Herndon JE, Cooper B, Perry MC, Vinciguerra V, and Mason-Coughlin Kristine: Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the Cancer and Leukemia Group B. Annals of Oncology 3:727-732, 1992.
  9. Lyss AP, Perry MC, Goutsou M, Propert K, Mason-Coughlin K, and Green MR: Intensive etoposide and carboplatin chemotherapy for advanced non-small cell lung cancer: A phase II trial of the Cancer & Leukemia Group B. Am J Clin Onc 15(5):399-404, 1992.
  10. Green MR, Kreisman H, Doll DC, Lyss A, Clamon G, Goutsou M, Perry MC, and Propert KJ: Carboplatin in non-small cell lung cancer: An update on the Cancer and Leukemia Group B Experience. Seminars in Oncology 19(1), Suppl 2:44-49, 1992.
  11. Aisner J, Whitacre MY, Budman DR, Propert K, Strauss G, Van Echo DA, and Perry MC: Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer. Cancer Chemother & Pharmacol 29(6):435-8, 1992.
  12. Brownson RC, Novotny TE, Perry MC: Cigarette smoking and adult leukemia, a meta-analysis. Arch Intern Med 153:469-475, 1993.
  13. Luikart SD, Goutsou M, Mitchell, ED, Van Echo DA, Modeas CR, Propert KJ, O'Donnell J, Difino S, Perry MC, and Green MR: Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. Am J Clin Oncol(CCT) 16(2):127-131, 1993.
  14. Patterson WP and Perry MC: Chemotherapeutic toxicities: A comprehensive overview. Contemp Onc 7:57-64, 1993.
  15. Hinson JA and Perry MC: Small-cell lung cancer. CA-A Cancer Journal for Clinicians 43:216-225, 1993.
  16. Clamon G, Herndon J, Perry MC, Ozer H, Kreisman H, Maher T, Ellerton J, and Green MR: Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer & Leukemia Group B. J Natl Cancer Inst 85(4):316-20, 1993.
  17. Hansen H, Perry M, Arriagada R, Chastang C, Drings P, _sterlind K, et al: Treatment evaluation. Lung Cancer 10(1):S7-S9, 1994.
  18. Bunn P, Arriagada R, Choi N, Feld R, Gregor A, Perry M, et al: Combined modality therapy in small cell lung cancer. Lung Cancer 10(1):S25-S28, 1994.
  19. Smith JP, Doll D, Croitoru R, Thornton C, Perry MC: Effects of octreotide on advanced colon cancer. J Clin Gastroenterol 18(3):245-247, 1994.
  20. Arriagada R, Pignon JP, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Osterlind K, Tattersall MHN, and Wagner H: Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Research 14:333-336, 1994.
  21. Ahles TA, Silberfarb PM, Rundle AC, Holland JC, Kornblith AB, Canellos GP, Green MR, Perry MC: Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for Cancer and Leukemia Group B. Psychother Psychosom 62:193-199, 1994.
  22. Kiang DT, Kennedy BJ, Younger J, Perry MC, Schilling A, Faraggi D, Korzun AH, Nowak B, and Wood W: Alternating chemotherapy for metastatic breast cancer - a pilot study based on tumor marker kinetics. Cancer 75(3):826-30, 1995.
  23. Bitran JD, Green MR, Perry MC, Hollis DR, Herndon JE for CALGB: A phase II study of recombinant interferon-gamma as maintenance therapy following combination chemotherapy for patients with extensive small cell lung cancer. A role for biologic maintenance therapy? Am J Clin Oncol (CCT) 18(1):67-70, 1995.
  24. Aisner J, Cirrincione C, Perloff M, Perry MC, Budman D, Abrams J, Panasci L, Muss H, Citron M, Holland J, Wood W, and Henderson IC: Combination chemotherapy for metastatic or recurrent carcinoma of the breast: a randomized phase III trial comparing: cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) versus vinblastine, doxorubicin, thiotepa, and halotestin (VATH) versus VATH alternating with cyclophosphamide, methotrexate, 5-fluorouracil, vinblastine, and prednisone (CMFVP) Cancer and Leukemia Group B Study 8281. J Clin Oncol, 13(6):1443-1452, 1995.
  25. Muscato JJ, Cirrincione C, Clamon G, Perry MC, Omura G, Berkowitz I, Reid T, Herndon JE, and Green MR: Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: A Cancer & Leukemia Group B Study. Lung Cancer 13:285-294, 1995.
  26. Ewy MF, Demmy TA, Perry MC, Krishnan MS, Curtis JJ: Massive phrenic perineurioma mimicking an unresectable cardiac tumor. Annals of Thoracic Surgery 60:188-189, 1995.
  27. Murrell HJ, Perry MC, Muscato JJ, Dorr VJ, Wilkes JD, Doll DC: Hodgkin?s disease: is staging laparotomy still necessary? Semin Oncol 22:15-25, 1995.
  28. Rapp JS, Perry MC: Extensive stage small cell lung cancer: determining suitability for outpatient management of febrile neutropenia. Semin Oncol 23:15-22, 1996.
  29. Mitchell EP, Perry MC, Luikart SD, Cirrincione CT, Van Echo DA, Herndon JE 2nd, Maurer LH, Clamon G, Green MR: A phase I/II trail of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group b study. Lung Cancer 15 (2):215-23, 1996.
  30. Perloff M, Norton L, Korzun A, Wood W, Carey R, Gottlieb A, Bank A, Silver R, Perry MC, Holland J: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a noncross-resistant regimen: A CALGB Study. J Clin Oncol 14(5):1589-98, 1996.
  31. Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR: Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: A Cancer & Leukemia Group B Study (CALGB 8832).
  32. Perry, MC: Future Directions in the Therapy of Small Cell Lung Cancer. Chest Surgery Clinics of North America 7(1):183-193, 1997.
  33. Dawn B, Perry M: Bilateral non-hodgkin's lymphoma of the breast mimicking mastitis. Southern Med Journ 90(3):328-329, 1997.
  34. Dorr V, Perry, M: Adjuvant therapy for Stage I and II non-small cell lung cancer. Hem/Onc Clinics of North America 11(2): 267-278, April 1997.
  35. Perry MC, Deslauriers J, Albain KS, Choi NC, Depierre A, Johnston MR, Lacquet LK, Payne DG, Putnam JB, Sculier JP, Shepherd FA: Induction treatment for resectable non-small cell lung cancer. Lung Cancer Supplement 1, S15-S18, 1997.
  36. Jett J, Reins R, Kvale P, McCloud T, Miller Y, Perry M, Sause W, Silvestri G, Stover D, Spiro S, Travis W: Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 156: 320-332, 1997.
  37. Niell, HB, Miller AA, Clamon GH, Perry MC, Crawford J, Green MR: A phase II study evaluating the efficacy of carboplatin, etoposide, and psclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Sem in Onc, Vol 24, No 4, Suppl 12 S12-130-S12-134, 1997.
  38. Green MR, Perry MC, Aisner J, Herndon J, Kornblith A, Holland JC: Psychological and neuropsychological functioning of patients with limited small cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin, a study by the Cancer & Leukemia Group B. J Clin Oncol.
Book Chapters
  1. Donehower RC, Abeloff MD, Perry MC: Selection of patients for chemotherapy in Clinical Oncology. Editors Abeloff MD, Armitage JO, Lichter AS, and Niederhuber JE. Churchfill Livingstone International, 1995.
  2. Perry MC: Genitourinary, Gastrointestinal, and Other Complications in High Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Second Editiion. Edited by JO Armitage, KH Antman. Williams & Wilkins, 1995.
  3. Westgate SJ, Perry MC: Toxicity of combined modality therapy in Comprehensive Textbook of Thoracic Oncology. Williams and Wilkins, 1996.
  4. Shahab N, Perry MC: DNA topoisomerase inhibitors in The Chemotherapy Sourcebook Second Edition, Williams & Wilkins, 1996.
  5. King PD, Perry MC. Hepatotoxicity in The Chemotherapy Sourcebook Second Edition, Williams & Wilkins, 1996.
Books
  1. Perry MC and Yarbro JW, editors. Toxicity of Chemotherapy. Grune and Stratton, 1984.
  2. Braun SR, editor; Everett ED, Perry MC, Sunderrajan EV, associate editors. Concise Textbook of Pulmonary Medicine. Elsevier, 1989.
  3. Perry MC, editor. The Chemotherapy Source Book, Williams & Wilkins, 1992.
  4. Aisner J, Arriagada R, Green MR, Martini N, Perry MC, editors. Comprehensive Textbook of Thoracic Oncology. Williams & Wilkins, 1996.
  5. Perry MC, editor. The Chemotherapy Source Book Second Edition, Williams & Wilkins, 1996.
Dr. Anderson
Manuscripts
  1. Benitz W, Kelley R, Anderson C, Lorant D, Bernfield M. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol, 2:13-24, 1990.
  2. Anderson, CM. Sodium chloride treatment of amphotericin B nephrotoxicity--standard of care? Western J Med. 162: 313-317, 1995.
  3. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology. 9 (11): 1149-1158, 1995.
  4. Anderson CM, Walters RS, Hortobagyi GN. Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early stage breast cancer. Am J Clin Oncol (CCT) 19: 556-568, 1996.
  5. Anderson CM, Buzaid AC, Sussman JJ, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Sewa S, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. 8(2):149-155,1998
  6. Anderson CM, Pusztai L, Palmer, J, Cabanillas F, Ellerhorst J. Coincident renal cell carcinoma and non-Hodgkin lymphoma: The MD Anderson experience and review of the literature. J Urol 159(3):714-717, 1998.
  7. Anderson CM, Bueso-Ramos CE, Wallner SA, Albitar M, Rosenzweig TE, Koller CA. De novo acute Myelogenous Leukemia associated with plasma cell dyscrasia: two cases and an update of literature. Leukemia & Lymphoma.32 (3-4): 385-390, 1999.
Book Chapters
  1. Anderson CM, Legha SS, Tabacof J. "Malignant melanoma: biology, diagnosis, and management." in Medical Oncology: A Comprehensive Review. 2nd Ed. Pazdur R, ed. PRR, Inc., Huntington, NY. pp. 493-509, 1995.
  2. Anderson CM, Buzaid AC, Grimm EA. "The interaction of chemotherapy and biological response modifiers in the treatment of melanoma." in Drug Resistance. Hait WN, ed. Kluwer Academic Publishers, Inc., Norwell, MA. pp. 357-380, 1996.
  3. Anderson CM, Buzaid AC, Ali-Osman F, Braunschweiger PG, Grimm EA. "Biochemotherapy in the treatment of advanced melanoma: Clinical results and potential mechanisms of anticancer activity." in Progress in Anti-Cancer Chemotherapy. Khayat D, Hortobagyi GN., eds. Blackwell Science, Inc., Cambridge, MA. pp. 68-87, 1997.
  4. Anderson CM. "Poor translation, good prognosis." In Medical Mysteries: Case based learning in internal medicine. Weber KT, ed. University of Missouri Printing Services, Columbia, MO, 1997.
  5. Anderson CM, Wilkes JD. "Malignant melanoma." in Companion Handbook to the Chemotherapy Sourcebook. Perry MC, Anderson CM, Dorr V, Wilkes, JD, editors. Williams & Wilkins Publishing, Baltimore, MD. pp. 57-64, 1999.
  6. Anderson CM, Rasool H. "Biologic Therapy of Cancer." In Hematology/Oncology Secrets. 2nd Ed. Hanley & Belfus, Philadelphia, PA pp. 206-210, 1998
  7. Anderson CM. "Chemotherapeutic agents-drug profiles." in Companion Handbook to the Chemotherapy Sourcebook. Perry MC, Anderson CM, Dorr V, Wilkes, J, editors. Williams & Wilkins Publishing, Baltimore, MD. pp. 407-473, 1999.
Dr. Wooldridge
Original Articles
  1. Wooldridge, J.E., Ballas, Z., Krieg, A.M., and Weiner, G.J. Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. Blood 89 (8): 2994-8, 1997.
  2. Weiner, G.J., Liu, H-M, Wooldridge, J.E., Dahle, C.E. and Krieg, A.M. Immunostimulatory Oligodeoxynucleotides containing CpG Motif are Effective as Immune Adjuvants in Tumor Antigen Immunization. Proceedings of the National Academy of Sciences USA, 94: 10833-7, 1997.
  3. Wooldridge, J.E., Dahle, C.E., and Weiner, G.J. T-cell Activation Induced by Anti-CD3 x Anti-B-cell Lymphoma Monoclonal Antibody is Enhanced by Pretreatment of Lymphoma Cells with Soluble CD40 Ligand. Cancer Immunology and Immunotherapy, 45: 724-729, 1997.
Book Chapters
  1. Wooldridge, J.E. Chemotherapy of Gastrointestinal Malignancies. Chemotherapy Sourcebook, 3rd ed. Perry, M.C., editor. (in preparation)
  2. Wooldridge, J.E. Chemotherapy Regimens. Chemotherapy Sourcebook, 3rd ed. Perry, M.C., editor. (in preparation)
Webmaster | ©2006 Curators of the University of Missouri DMCA and other copyright information
All rights reserved. An equal opportunity/ADA institution.
Last Revised: 10/24/2005